As the Uganda Ministry of Health plans for national rollout of this new option for women, PATH’s DMPA-SC Self-injection Best Practices initiative is gathering information about how the practice can be designed and implemented at a broader scale. The team in Uganda has applied user-centered design techniques to develop, implement, and evaluate self-injection program models across delivery channels: public-sector facilities, community-based distribution, private-sector outlets, and safe spaces for young women and adolescent girls. As of late 2018, program data showed that more than 7,000 women were using self-injection contraception across four districts.
As PATH evaluates these programs, we are regularly sharing insights and lessons learned. If you are planning a self-injection program in your country please feel free to email FPoptions@path.org. For more information, see the resources listed below, visit www.path.org/dmpa-sc, orsign up for our newsletter.
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate
Sayana Press is a registered trademark of Pfizer Inc.
“It saves time to inject at home, and it’s private. Another reason is you get courage. I used to fear the needle so much.”— Self-injection client, Uganda
Overview and training resources
- Self-injected subcutaneous DMPA: A new frontier in advancing contraceptive access and use for women
- Self-injection: Empowering Women Who Want to "Stick" with Contraception
- DMPA-SC training materials for providers and self-injection clients